Novartis Modernises Supply Chain to Deliver RLT Medicines On Time
Novartis’ operations president Steffen Lang describes how the company is scaling and modernising its supply chain and manufacturing infrastructure to deliver RLT medicines safely and on time to patients. The personalised dosing makes logistics unforgiving, especially across 30+ countries with added regulatory complexity. Novartis is also building isotope-network capacity and redundancy to reduce the risk of treatment delays or failures.